#11. TYK2 Inhibitor Landscape and Pipeline (05/09/2025)

In this episode, we are providing a comprehensive review of TYK2 inhibitors as of May 2025, highlighting significant advancements and considerations in dermatology--particularly one in phase-3 clinical trials developed by AI. Several articles focus on innovative treatments, including AI-powered drug design for conditions like psoriasis, the use of a novel laser surgery system for solar lentigines, and the integration of nonsteroidal topical therapies for plaque psoriasis. Important clinical topics are also addressed, such as recognizing key differences between atopic dermatitis and prurigo nodularis, exploring the causes and prevention of female hair loss, and reviewing risks and management strategies for pediatric melanoma. Additionally, the sources cover the concerning report regarding benzene formation in benzoyl peroxide products at room temperature and provide detailed information about the TYK2 inhibitor landscape, discussing approved therapies like deucravacitinib and pipeline candidates developed with potential aid from artificial intelligence.